Antibody-drug conjugates (ADCs) are a targeted class of anticancer therapeutics that combine the specificity of a monoclonal antibody with the potency of a cytotoxic payload. By linking an antibody, a linker, and a cytotoxic drug into one engineered molecule, ADCs are designed to selectively deliver potent anticancer agents to tumor cells while reducing damage to healthy tissue.
AntibodySystem provides an end-to-end ADC research portfolio, including anti-payload antibodies for DAR and PK/PD bioanalysis, as well as research-grade reference ADCs covering major payload classes and clinically relevant tumor targets.
What Is an Antibody-Drug Conjugate?
An ADC is composed of three engineered components:
- Antibody: Recognizes and binds a tumor-associated antigen on the cancer cell surface.
- Linker: Connects the antibody and payload and controls payload release inside the target cell.
- Cytotoxic payload: A highly potent drug that induces cancer cell death, often through DNA damage or microtubule disruption.
After the antibody binds to its target antigen, the ADC-antigen complex is internalized into the cancer cell. The linker then releases the cytotoxic payload, leading to apoptosis of the target cancer cell.
Why ADC Research Requires Specialized Reagents
ADC research and development require multiple analytical tools. Researchers need to confirm antibody specificity, evaluate payload release, measure drug-to-antibody ratio, monitor pharmacokinetics and pharmacodynamics, and compare reference ADCs across different target and payload classes.
AntibodySystem supports these workflows with anti-payload antibodies and research-grade ADC reference drugs from a single source.
AntibodySystem ADC Portfolio at a Glance
- 53 ADC reference drugs: Research-grade ADC biosimilars for comparative studies
- 35 antigen targets: Including HER2, TROP2, EGFR, BCMA, Nectin-4, CD19, CD22, CD30, CD33 and more
- 5 anti-payload antibodies: For detection and quantification of key ADC payloads
- 7 payload classes: Supporting major ADC research workflows
- >90% purity: Verified by SEC
- Research Use Only: Not for clinical, diagnostic, or therapeutic use
Anti-Payload Antibodies for DAR and PK/PD Bioanalysis
Anti-payload antibodies are essential for detecting and quantifying cytotoxic payloads in ADC research. They are commonly used in ELISA-based workflows for drug-to-antibody ratio analysis, pharmacokinetic studies, pharmacodynamic studies, and ADC bioanalysis.
| Catalog No. | Product Name | Detects | Host | Application |
|---|---|---|---|---|
| RGP34301 | Anti-MMAE Antibody (SAb2492) | MMAE | Mouse | ELISA |
| RGP34303 | Anti-MMAF Antibody (R4E31) | MMAF | Mouse | ELISA |
| RGP16201 | Anti-DM1 Antibody (SAb2290) | DM1 | Mouse | ELISA |
| RGP34302 | Anti-SN38 Antibody (SAb2493) | SN38 | Rabbit | ELISA |
| RGP33501 | Anti-Deruxtecan/DXd Antibody (SAb2488) | Deruxtecan | Mouse | ELISA |
Selected ADC Reference Drugs
AntibodySystem offers research-grade ADC reference drugs covering major ADC targets and payload classes. These reference ADCs are supplied for research use only and are intended for assay development, comparative testing, and analytical research.
| Catalog No. | Product Name | Target |
|---|---|---|
| DHC09698 | Trastuzumab deruxtecan | HER2 |
| DHC09699 | Trastuzumab emtansine | HER2 |
| DHC43399 | Datopotamab deruxtecan | Trop2 |
| DHC43398 | Sacituzumab govitecan | Trop2 |
| DHB86996 | Depatuxizumab mafodotin | EGFR |
| DHJ41099 | Enfortumab vedotin-ejfv | Nectin-4 |
| DHD80999 | Brentuximab vedotin | CD30 |
| DHF92499 | Belantamab mafodotin | BCMA |
| DHD10899 | Loncastuximab tesirine | CD19 |
| DHD00699 | Tisotumab vedotin | Tissue Factor |
Key Benefits for ADC Researchers
- Complete ADC toolkit: Anti-payload antibodies and 50+ reference ADCs from one source
- Payload detection: Detect and quantify MMAE, MMAF, DM1, SN38, and Deruxtecan/DXd
- Broad target coverage: 35 clinically relevant targets including HER2, TROP2, EGFR, BCMA, Nectin-4 and hematologic cancer markers
- Research-grade quality: >90% purity by SEC and verified lot-to-lot consistency
- Fast availability: In-stock products with 5–7 working days delivery
Research Use Only Notice
All ADC portfolio products are supplied for Research Use Only (RUO). They are not intended for clinical, diagnostic, or therapeutic use.
Request ADC Product Information
Contact Dana Bioscience for ADC product datasheets, validation data, trial-size samples, quotation, and distributor support. Additional targets, payloads, and custom formats are available on request.